Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Abstract Background Hand-foot syndrome (HFS) is a side effect of skin related to pegylated liposomal doxorubicin (PLD) application. Moderate to severe hand-foot syndrome (MSHFS) might have a serious impact on patients’ quality of life and treatment. However, information on risk factors for the devel...

Full description

Bibliographic Details
Main Authors: Guohua Liang, Wenjie Ma, Yanfang Zhao, Eryu Liu, Xiaoyu Shan, Weiwei Ma, Dabei Tang, Liru Li, Xingjian Niu, Wenhui Zhao, Qingyuan Zhang
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Cancer
Subjects:
Breast Cancer
Pegylated liposomal doxorubicin
Hand-foot syndrome
Risk factors
Predictive model
Online Access:https://doi.org/10.1186/s12885-021-08028-8

Internet

https://doi.org/10.1186/s12885-021-08028-8

Similar Items